A carefully managed journey built around informed consent, quality controls, and responsible distribution.
In medicine today, regenerative therapies can be derived from four different sources: umbilical cord tissue, embryonic tissue, bone marrow, and adipose tissue.
However, some sources have their drawbacks. Embryonic cells raise ethical concerns, while bone marrow- and adipose tissue-derived cells can only be retrieved through invasive surgical procedures.
Umbilical cord tissue retrieval, which takes place immediately after the umbilical cord is cut upon delivery, is non-invasive and ethically sound. In addition to containing a wide variety of cells, umbilical cord tissue is a source of growth factors that also play an important role in regenerative medicine.
Four connected stages support a documented and carefully controlled journey.
The option to donate umbilical cord tissue is offered to expecting mothers by participating hospitals. Mothers who choose to donate undergo a screening and sign informed consent forms, indicating they consent to have their umbilical cord tissue used in medicine.
Umbilical cord tissue and blood extraction is conducted by a nurse immediately following delivery. Tissue is processed in a cGMP- and GTP-compliant laboratory.
BioGenix applies AATB regulatory standards to screen umbilical cord tissue for quality in our sterile, FDA-compliant laboratory.
BioGenix distributes directly to doctors and healthcare institutions. Standardized concentrations allow physicians to accurately measure treatment dose. For purchasing information, please contact us.
Contact us